| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -52,441 | -36,071 |
| Stock-based compensation expense | 5,032 | 3,799 |
| Depreciation expense | 1,234 | 832 |
| Non-cash interest expense | 1,561 | 1,010 |
| Non-cash lease expense | 579 | 381 |
| Loss on extinguishment of debt | 0 | 0 |
| Change in fair value of derivative liability | 215 | 190 |
| Prepaid expenses and other assets | 117 | 574 |
| Other receivables | 0 | 0 |
| Accounts payable, accrued expenses and other liabilities | -3,553 | -2,348 |
| Deferred revenue | 0 | 0 |
| Operating lease liability | -1,348 | -951 |
| Net cash used in operating activities | -49,268 | -34,112 |
| Purchases of property and equipment | 0 | 0 |
| Net cash used in investing activities | 0 | 0 |
| Proceeds from at the market offering of common stock, net of issuance costs | 3,621 | 347 |
| Proceeds from drawdown of term loans | 0 | 0 |
| Payment of debt issuance costs | 0 | 0 |
| Repayment of term loan | 0 | 0 |
| Proceeds from issuances under employee stock purchase plan | 41 | 41 |
| Proceeds from stock option exercises | 0 | 0 |
| Net cash provided by financing activities | 3,662 | 388 |
| Net decrease in cash, cash equivalents and restricted cash and cash equivalents | -45,606 | -33,724 |
| Cash and cash equivalents at beginning of period | 112,215 | - |
| Cash and cash equivalents at end of period | 66,609 | - |
Werewolf Therapeutics, Inc. (HOWL)
Werewolf Therapeutics, Inc. (HOWL)